Jerry Xiao - DiaMedica Therapeutics Director

DMAC Stock  USD 2.65  0.07  2.57%   

Director

Dr. Jerry Xiao serves as Director of the Company. Dr. Xiao was the Managing Director of Hermed Capital since December 2014 and previously was the head of Business Development and Associate General Manager of the Research and Development Center of Shanghai Fosun Pharmaceutical Group from June 2008 to November 2014 where he was the deputy chief of the IPO team for the Fosun Pharma Listing in Hong Kong. since 2016.
Tenure 8 years
Address 301 Carlson Parkway, Minneapolis, MN, United States, 55305
Phone763 496 5454
Webhttps://www.diamedica.com

DiaMedica Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.3002) % which means that it has lost $0.3002 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4677) %, meaning that it created substantial loss on money invested by shareholders. DiaMedica Therapeutics' management efficiency ratios could be used to measure how well DiaMedica Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of March 28, 2024, Return On Capital Employed is expected to decline to -0.43. In addition to that, Return On Assets is expected to decline to -0.38. At present, DiaMedica Therapeutics' Non Current Assets Total are projected to decrease significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 56.4 M, whereas Non Currrent Assets Other are forecasted to decline to (0.94).
The company currently holds 400 K in liabilities. DiaMedica Therapeutics has a current ratio of 24.99, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist DiaMedica Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, DiaMedica Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like DiaMedica Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for DiaMedica to invest in growth at high rates of return. When we think about DiaMedica Therapeutics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Mark PruzanskiEquillium
50
Dennis AusielloSeres Therapeutics
72
Tadataka YamadaAgilent Technologies
74
Werner CautreelsSeres Therapeutics
N/A
Daniel PodolskyAgilent Technologies
67
Lorence KimSeres Therapeutics
43
Meryl ZausnerSeres Therapeutics
61
Aharon YaariMediwound
63
Anders Forseback23Andme Holding Co
N/A
Martha DemskiEquillium
65
Americo Romano23Andme Holding Co
58
Peter HuttSeres Therapeutics
80
Carina Olofsson23Andme Holding Co
42
Dow WilsonAgilent Technologies
61
AnnChristine Hvittfeldt23Andme Holding Co
49
Arturo Testa23Andme Holding Co
37
Helena Herlogsson23Andme Holding Co
N/A
Mala AnandAgilent Technologies
53
Johannes Tiden23Andme Holding Co
34
Charles McDermottEquillium
45
George ScangosAgilent Technologies
72
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota. Diamedica Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people. DiaMedica Therapeutics (DMAC) is traded on NASDAQ Exchange in USA. It is located in 301 Carlson Parkway, Minneapolis, MN, United States, 55305 and employs 18 people. DiaMedica Therapeutics is listed under Biotechnology category by Fama And French industry classification.

Management Performance

DiaMedica Therapeutics Leadership Team

Elected by the shareholders, the DiaMedica Therapeutics' board of directors comprises two types of representatives: DiaMedica Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DiaMedica. The board's role is to monitor DiaMedica Therapeutics' management team and ensure that shareholders' interests are well served. DiaMedica Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DiaMedica Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Paul Papi, Vice President - Business Development
James Parsons, Director
Ambarish Shah, Chief Officer
Richard Pilnik, Independent Chairman of the Board
Julie CCRP, Senior Operations
Jerry Xiao, Director
Dominic Cundari, Chief Officer
David Wambeke, Chief Officer
Scott CPA, CFO Secretary
Todd Verdoorn, Chief Scientific Officer
MS MD, Independent Consultant
Scott CA, CFO Sec
Edward Calamai, Consulting Manufacturing
Scott Kellen, CFO, Corporate Secretary
Michael Giuffre, Independent Director
Lorianne MD, Chief Officer
Dietrich MBA, CEO President
Rick Pauls, President CEO, Director
Harry Alcorn, Director

DiaMedica Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is DiaMedica Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with DiaMedica Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DiaMedica Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DiaMedica Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against DiaMedica Stock

  0.42SNDL SNDL Inc Buyout TrendPairCorr
The ability to find closely correlated positions to DiaMedica Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DiaMedica Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DiaMedica Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DiaMedica Therapeutics to buy it.
The correlation of DiaMedica Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DiaMedica Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DiaMedica Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DiaMedica Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether DiaMedica Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of DiaMedica Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Diamedica Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Diamedica Therapeutics Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DiaMedica Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.
For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.
Note that the DiaMedica Therapeutics information on this page should be used as a complementary analysis to other DiaMedica Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Complementary Tools for DiaMedica Stock analysis

When running DiaMedica Therapeutics' price analysis, check to measure DiaMedica Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DiaMedica Therapeutics is operating at the current time. Most of DiaMedica Therapeutics' value examination focuses on studying past and present price action to predict the probability of DiaMedica Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DiaMedica Therapeutics' price. Additionally, you may evaluate how the addition of DiaMedica Therapeutics to your portfolios can decrease your overall portfolio volatility.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Is DiaMedica Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DiaMedica Therapeutics. If investors know DiaMedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DiaMedica Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.60)
Return On Assets
(0.30)
Return On Equity
(0.47)
The market value of DiaMedica Therapeutics is measured differently than its book value, which is the value of DiaMedica that is recorded on the company's balance sheet. Investors also form their own opinion of DiaMedica Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is DiaMedica Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DiaMedica Therapeutics' market value can be influenced by many factors that don't directly affect DiaMedica Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DiaMedica Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if DiaMedica Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DiaMedica Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.